This site is intended for healthcare professionals

This video is worth 0.1 CPD credits. CPD Dashboard

This video is worth 0.1 CPD credits. Upgrade to Pro

Short-acting beta 2 agonists in asthma: MHRA update

Posted 18 Jul 2025

Dr Anish Kotecha FRCGP FAcadMEd GPwERLM MBBCh BSc

Dr Anish Kotecha summarises the changes required when prescribing short-acting beta 2 agonists in asthma, following a recent MHRA update and the revision of UK asthma guidelines in 2024.

Reference

(1) MHRA. 2025. https://www.gov.uk/drug-safety-update/short-acting-beta-2-agonists-saba-salbutamol-and-terbutaline-reminder-of-the-risks-from-overuse-in-asthma-and-to-be-aware-of-changes-in-the-saba-prescribing-guidelines.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.